EYE 0.00% 24.0¢ nova eye medical limited

Nova Eye Medical (EYE) Discussion, page-2480

  1. 1,665 Posts.
    lightbulb Created with Sketch. 163
    I would personally temper my expectations here a little on near term profitability.

    Do we know which form of profitability that the company is referring to? I prefer NPAT because it is what is available to shareholders. Companies however typically prefer EBITDA because it is easier to generate.

    EBITDA breakeven is possible on a monthly basis towards the end of the calendar year but NPAT breakeven looks like it is futher six months away to me and will require maybe up to $35m of revenue to achieve.

    If I had to guess I would say we are probably looking at a $3-4m NPAT loss in the second half of FY24, versus a $5.6m loss in the first half.

    The good news for the patient is that if/when it becomes apparent that NPAT profitability is guaranteed then I think we can see the big re-rate from 2x sales to 5x sales.
 
watchlist Created with Sketch. Add EYE (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
0.000(0.00%)
Mkt cap ! $54.91M
Open High Low Value Volume
24.0¢ 24.5¢ 24.0¢ $110.1K 458.4K

Buyers (Bids)

No. Vol. Price($)
4 432506 23.5¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 169560 3
View Market Depth
Last trade - 16.10pm 25/07/2024 (20 minute delay) ?
EYE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.